Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income from Non-Controlling Interests: 2014-2018

Historic Income from Non-Controlling Interests for Coherus Oncology (CHRS) over the last 4 years, with Sep 2018 value amounting to -$18,000.

  • Coherus Oncology's Income from Non-Controlling Interests fell 350.00% to -$18,000 in Q3 2018 from the same period last year, while for Sep 2018 it was -$72,000, marking a year-over-year increase of 47.45%. This contributed to the annual value of -$70,000 for FY2018, which is 39.66% up from last year.
  • According to the latest figures from Q3 2018, Coherus Oncology's Income from Non-Controlling Interests is -$18,000, which was up 61.70% from -$47,000 recorded in Q2 2018.
  • Coherus Oncology's Income from Non-Controlling Interests' 5-year high stood at $111,000 during Q4 2014, with a 5-year trough of -$224,000 in Q2 2015.
  • Over the past 3 years, Coherus Oncology's median Income from Non-Controlling Interests value was -$44,000 (recorded in 2017), while the average stood at -$57,909.
  • As far as peak fluctuations go, Coherus Oncology's Income from Non-Controlling Interests soared by 95.79% in 2017, and later tumbled by 350.00% in 2018.
  • Over the past 5 years, Coherus Oncology's Income from Non-Controlling Interests (Quarterly) stood at $111,000 in 2014, then tumbled by 270.27% to -$189,000 in 2015, then skyrocketed by 87.83% to -$23,000 in 2016, then surged by 91.30% to -$2,000 in 2017, then tumbled by 350.00% to -$18,000 in 2018.
  • Its Income from Non-Controlling Interests was -$18,000 in Q3 2018, compared to -$47,000 in Q2 2018 and -$5,000 in Q1 2018.